Efficacy and safety of fezolamine in depressed patients.

Abstract

Forty-two outpatients with major depressive disorder were treated with oral fezolamine in a 6-week, three-center open-label study. Therapy was initiated at 100 mg/day; thereafter dosage was increased based on the response of the patient. Maintenance dosage usually ranged between 100 and 450 mg/day. Clinically significant improvement relative to the patient's prestudy state was observed after 2 weeks in both patient and physician-rating scales. Fifty-five percent of patients improved their Hamilton Psychiatric Rating Scale for Depression (HAM-D) scores by more than 50%. The median dose associated with a clinically significant response was 245 mg/day. Five of the 6 patients who dropped out did so because of gastrointestinal adverse effects. The most common adverse effects were nausea (36%), headache (29%), constipation (26%), and dry mouth (24%).

• Authors: S Zisook, J Mendels, D Janowsky, J Feighner, J C Lee, A Fritz
• Journal: Neuropsychobiology (Neuropsychobiology) Vol. 17 Issue 3 Pg. 133-8 ( 1987) ISSN: 0302-282X [Print] Switzerland
• PMID: 3683802 (Publication Type: Journal Article)

Chemical References

• Antidepressive Agents
• Pyrazoles
• fezolamine

Topics

• Adult
• Antidepressive Agents (therapeutic use)
• Depressive Disorder (drug therapy, psychology)
• Female
• Humans
• Male
• Pilot Projects
• Psychiatric Status Rating Scales
• Pyrazoles (adverse effects, therapeutic use)